Histopathologic Outcomes
Tumor
REGRESSION, DISEASE, RECURRENCE, TUMOR
Substantial reductions in T stage, N stage, and EMVI were seen in the NAC group, compared with controls (Data Supplement). Notably, T4 disease was reduced from 107 of 351 (31%) in the control group to 142 of 686 (21%) after NAC, (A) Tumor regression grade by treatment allocation in the NAC group, and recurrence after surgery by regression grade in (B) NAC and (C) control groups. NAC, neoadjuvant chemotherapy; RR, rate ratio.Of 351 control patients undergoing surgery, 83 (24%) did not meet standard criteria for AC out-with the trial